| Metric | Value ($ M) | vs Q1 FY26 |
|---|---|---|
| Revenue | 1.11 | 382.6% |
| Total Income | 1.11 | 382.6% |
| Expenditure | 45.20 | 122.8% |
| PBT | -43.39 | 125.2% |
| Net Profit | -43.39 | 125.2% |
| OPM | — | |
| NPM | — | |
| EPS | -0.20 | 122.2% |
Tenaya Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
06 Aug 2026 · 6 Aug, 1:49 am
Summary
Tenaya Therapeutics reported its second quarter 2026 financial results and provided a business update, highlighting positive interim clinical trial data for its lead candidates TN-201 and TN-401. The company experienced a net loss of $43.4 million ($0.20 per share) for the quarter, an increase from the prior year, largely due to a non-cash impairment charge related to lease termination. However, operational expenses saw reductions in R&D and G&A compared to the previous year. The company also announced progress in its pipeline, including advancing TN-301 towards Phase 2 trials, and secured a $10 million upfront payment from an Alnylam collaboration, extending its cash runway through Q3 2027.
Key Highlights
- 1
Tenaya Therapeutics announced positive interim data from the MyPEAK™-1 and RIDGE™-1 clinical trials in the second quarter of 2026, demonstrating meaningful improvements in key disease characteristics.
- 2
The company expects additional data releases and updates on regulatory discussions for pivotal trial plans for TN-201 and TN-401 in the fourth quarter of 2026.
- 3
TN-301 is advancing toward a Phase 2 trial start in the second half of 2027, indicating pipeline progression.
- 4
A $10 million upfront payment was received from the Alnylam collaboration, extending the company's cash runway through Q3 2027.
- 5
Net loss for the second quarter of 2026 was $43.4 million, or $0.20 loss per share, compared to a net loss of $23.3 million, or $0.14 per share, in the same period of 2025, impacted by an impairment charge.
- 6
Research and development expenses were $16.6 million for Q2 2026, a slight decrease from $17.4 million in Q2 2025.
- 7
General and administrative expenses were $5.4 million for Q2 2026, down from $6.7 million in Q2 2025, reflecting cost reduction efforts.
Management Comments
Faraz Ali
The second quarter marked an important period of execution for Tenaya as we shared new safety and clinical benefit data for TN-201 and TN-401. We remain excited by the encouraging results emerging from our TN-201 MyPEAK-1 clinical trial in patients with MYBPC3-associated disease and the most recent RIDGE-1 data add to our confidence in TN-401’s potential as a highly promising candidate to address the underlying cause of PKP2-associated ARVC. We are engaging with regulators to discuss the efficient late-stage development and approval pathways for each candidate. We also believe that advancing TN-301 toward Phase 2 represents an opportunity to create significant value while further diversifying our pipeline. We remain focused on disciplined execution, efficient use of capital, and advancing programs with the greatest potential to deliver meaningful impact for patients and stockholders.
Informational and educational content only. Not investment advice.